Chimeric antigen receptor modified T-cells for cancer treatment
T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), an...
Saved in:
Main Authors: | Xiao Han, Yao Wang, Wei-Dong Han |
---|---|
Format: | article |
Language: | EN |
Published: |
KeAi Communications Co., Ltd.
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/5f052065f6bb40cbb3a2e894eb1bf860 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
by: Mehran Bahraini, et al.
Published: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
by: Cristina Aparicio, et al.
Published: (2021) -
A TCR-based Chimeric Antigen Receptor
by: Even Walseng, et al.
Published: (2017) -
Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression
by: Chungyong Han, et al.
Published: (2018) -
Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models
by: Nan Li, et al.
Published: (2021)